The patent, which provides protection until November 2027, is part of a family of patents and patent applications that protect Qualigen's FastPack "Laboratory in a Pouch" rapid immunoassay diagnostic technology.
"We are pleased to strengthen our intellectual property protection with the addition of this patent in China covering our core FastPack diagnostic technology," said Michael S. Poirier, chief executive officer of Qualigen. "We have consistently sought to protect, expand, and improve uses of our FastPack diagnostic technologies in the US and worldwide. As such, we now have over 40 issued patents in this space."
Qualigen is focused on the development, production and commercialisation of innovative medical technologies, including its flagship FastPack point-of-care immunoassay system and novel therapeutic technologies for treatment of cancers and infectious diseases.
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
Merck KGaA to acquire JSR Life Sciences chromatography business to expand Protein A capabilities
60 Degrees reports first patient has tested negative for babesiosis in tafenoquine study
INOVIO announces inducement grant to new employee
Hologic receives FDA clearance and CE mark for new gastrointestinal bacterial assays
LakeShore Biopharma receives Nasdaq delisting determination letter
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio
INOVIO to release Q2 2025 financial results on 12 August
Bavarian Nordic chikungunya vaccine enters Health Canada review process
Ondine Biomedical completes world-first ICU study with Steriwave nasal therapy